Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasilomod vs placebo in chemotherapy-naive metastatic castration-resistant prostate cancer (Asia)
CTR20131488Phase 3Suspended
- Sponsor
- Ipsen
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Tasilomod with Placebo (2 arms). Primary endpoint: Radiographic progression-free survival (rPFS). Started Sep 2014; status: suspended.
02
Drugs
tasquinimod
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20131488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131488.